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USE OF TIME-STAMPED HOSPITAL DATA TO EXAMINE CARE
PATTERNS OF ACUTE CORONARY SYNDROME PATIENTS
UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
Wang C1, He J1, McCollam PL2, Bae JP2, Grifﬁn BT1
1Solucient, Inc, Berkeley Heights, NJ, USA; 2Eli Lilly and Company,
Indianapolis, IN, USA
OBJECTIVES: Quality improvement initiatives in acute coro-
nary syndrome (ACS) such as CRUSADE have found marked
increase in treatment guideline adherence during the past several
years. This descriptive study used time-stamped data to examine
pharmacologic treatment and laboratory biomarker utilization
patterns in ACS patients who underwent percutaneous coronary
intervention (PCI). METHODS: The data source consisted of 19
hospitals throughout the U.S. that used time-stamp data from
January 2003–September 2004. ACS was identiﬁed in the dataset
using ICD-9 diagnosis codes for unstable angina and/or myocar-
dial infarction (MI). The time-stamp allowed more precise mea-
surement of drug administration and biomarker sampling.
Biomarker deﬁnition of MI was CK-MB >3 times upper limit of
normal, troponin I and myoglobin >1 times upper limit of
normal. RESULTS: A total of 6,282 ACS patients who had been
given clopidogrel were identiﬁed with adequate time-stamp
information. The most common recorded comorbid diagnoses
were ischemic heart disease 91.2%, hypertension 54.4%, lipid
disorder 57.9%, and diabetes 21.7%. Aspirin (ASA) plus clopi-
dogrel was received by 75.9% of patients and initiated on the
day of PCI in 88.3% of patients. The majority of initial ASA plus
clopidogrel administration was minus (-) 10 to plus (+) 14 hours
from PCI. GPIIb/IIIa inhibitors were received by 68.6% and
statins by 73% of patients, respectively during hospitalization.
Post-procedure (>8 hours after PCI) biomarker monitoring (CK-
MB, troponin I or myoglobin) was performed in 67.9% of
patients. The majority of testing was CK-MB or troponin I.
Results suggestive of MI were found in up to 67% of patients.
CONCLUSIONS: This novel examination of ACS treatment
using time-stamped data found ASA, clopidogrel; GPIIb/IIIa
inhibitors and statins were often used in this cohort. A wide
range of initial administration time for ASA plus clopidogrel
around PCI was found. Post-procedure biomarker monitoring
occurred frequently and was often positive.
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THIENOPYRIDINE THERAPY IN ACUTE CORONARY
SYNDROME PATIENTS RESIDING IN GERMANY
Lage MJ1, McCollam PL2, Bae JP2
1HealthMetrics Outcomes Research, LLC, Groton, CT, USA; 2Eli Lilly
and Company, Indianapolis, IN, USA
OBJECTIVES: The European Society of Cardiology consensus
treatment guidelines in 2002 support use of clopidogrel in many
ACS patients for secondary prevention of cardiac events. This
study is to examine clopidogrel patterns of use in acute coronary
syndrome (ACS) patients in Germany. METHODS: The data
source was the IMS Health, Disease Analyzer Mediplus-German
database, containing approximately 4.2 million de-identiﬁed
patient records from approximately 1000 participating practices.
The analysis period was January 1, 2001-September 1, 2004.
The index ACS event was identiﬁed using ICD-10 codes for
unstable angina or acute myocardial infarction. Patients were
included if they had ≥3 months of data before and 6 months after
an index ACS event and ≥1 prescription for clopidogrel after the
event. RESULTS: Of the 28,688 patients included in the ACS
cohort, 748 had at least one clopidogrel prescription (2.6%) and
met inclusion criteria. Mean age was 67.5 years; 68% were male.
The mean number of recorded comorbidities was 7.4. High cho-
lesterol, hypertension, angina, ischemic heart disease, and dia-
betes were most common. The recorded mean length of clopi-
dogrel therapy was 41 days. 74% of patients stopped therapy,
deﬁned as not on clopidogrel 28-days prior to end of follow-up.
A gap in therapy, deﬁned as late reﬁlls >14 days apart, was seen
in 89%. Concomitant cardiovascular drug therapies included:
calcium channel blocker (20.3%), beta-blocker (69.1%) and
statin (64.7%). CONCLUSION: This descriptive study suggests
clopidogrel is underutilized in ACS patients and long-term adher-
ence to therapy was poor as demonstrated by stoppages or gaps
in therapy.
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THE EFFECT OF GENDER ON HEALTH-RELATED QUALITY
OF LIFE AFTER CORONARY STENT IMPLANTATION
Brüggenjürgen B1, Mcbride D2,Willich SN1
1Charité—Universitätsmedizin Berlin, Institut für Sozialmedizin,
Epidemiologie und Gesundheitsökonomie, Berlin, Germany;
2Universitätsmedizin Berlin, Charité, Berlin, Germany
OBJECTIVE: The need for treatment of cardiac disease in
women can go unrecognised and access to appropriate health
care can be limited. We evaluated the effect of gender on changes
in long-term health-related quality of life (HRQoL) after coro-
nary stent implantation (CSI) in conventional treatment of coro-
nary artery disease (CAD). METHOD: In this prospective
comparative multi-centre cohort study in Germany, patients with
CAD undergoing coronary angioplasty were electively treated
with stents. Standardised questionnaires were completed by
patients at baseline, 3, 6, 12, and 18 months following angio-
plasty and documented patient health-related (SF-36) and
disease-speciﬁc (MacNew heart disease questionnaire) quality of
life, as well as clinical outcomes. RESULTS: From April until
August 2004, 103 women (16%, mean age 66, b11) und 546
men (mean age 64, b10) were treated with CSI. There were no
signiﬁcant differences in socio-demographic factors, cardiovas-
cular risk factors and severity of CAD. At baseline, all aspects
of HRQoL evaluated by SF-36 and MacNew were signiﬁcantly
poorer in women than in men (p = 0.004). Three months fol-
lowing stent implantation, the difference in improvement in the
SF-36 aspects of general health (p = 0.005), role emotional (p =
0.034) and the mental summary score (p = 0.027) was signiﬁ-
cantly greater in women than in men, although their actual
HRQoL remained signiﬁcantly lower in most aspects. After 6
months, the difference in improvement in women was signiﬁ-
cantly greater to baseline in the aspect of role emotional than
men (p = 0.019). Gender differences in improvement were not
demonstrated in the follow-up MacNew questionnaires. CON-
CLUSIONS: In comparison to men, baseline HRQoL in women
may be lower before receiving CSI treatment. However, three and
six months following implantation of a coronary stent, the 
difference in improvement in many aspects of HRQoL was
greater in women than in men. Women may have a wider range
of potential improvement after coronary stent implantation than
men.
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HEALTH RELATED QUALITY OF LIFE IN PATIENTS 
WITH CORONARY HEART DISEASE: A STUDY USING 
EQ-5D QUESTIONNAIRE
De Portu S1, Monzini M2, Galietti M3, Mantovani LG2
1University of Naples, Naples, Italy; 2Center of Pharmacoeconomics,
Milan, Italy; 3University of Milan, Milan, Italy
OBJECTIVES: Coronary heart disease (CHD) is nowadays the
most frequent cause of mortality and morbidity in industrialized
countries. In Europe it accounts for around two million deaths
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per year. CHD may adversely impact on the Quality of Life. The
objectives of the study were to describe Health-Related Quality
of Life (HR-QOL) in subjects with CHD and to compare their
health state with the health state of subjects without CHD.
METHODS: We selected subjects with CHD (Cases) from a rep-
resentative sample of the Italian general population aged from
40 to 79 years, enrolled in a population based naturalistic
prospective survey. We matched each of them by age and sex
with subjects without CHD disease (Controls). EuroQoL (EQ-
5D) was used to evaluate HR-QOL. We used Chi Square Test to
evaluate differences in the ﬁve dimensions of the EQ-proﬁle
between the two groups. Paired sample T test was used to eval-
uate differences in EQ-VAS. RESULTS: We analyzed two groups
of 98 subjects per group. The mean age was 64.7 (SD 8.6) years,
(69.4%) were male. More problems were reported in cases than
in controls in the mobility dimension, usual activities, and self
care and anxiety/depression dimensions. These differences
proved statistically signiﬁcant. Whereas in pain/discomfort
domain there was no signiﬁcant difference between the two
groups. Mean values of the visual analogue scale assessing global
health status indicated by case and control were 68.1 and 66.94,
respectively (P = 0.005). CONCLUSION: The study, comparing
subjects of the same age and sex with and without CHD, sug-
gests that the presence of CHD is associated with higher prob-
lems in HR.
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PORTUGUESE ACTIVE POPULATION HEALTH RELATED
QUALITY OF LIFE RESULTS USING THE SF-6D
Ferreira LN1, Ferreira PL2
1University of Algarve, Faro, Algarve, Portugal; 2University of Coimbra,
Coimbra, Coimbra, Portugal
OBJECTIVES: This study aims to describe the health related
quality of life (HRQOL) of the Portuguese population and inves-
tigates sociodemographic differences. METHODS: Subjects ran-
domly selected from the Portuguese active population (n = 2459)
were assessed using the SF-36, a generic measure of HRQOL,
which was converted into the preference-based SF-6D, following
the Brazier algorithm. Although the sample was randomly
selected, it differed slightly from the whole population. In order
to correct this, post-stratiﬁed statically techniques were used to
weight the initial results by gender and age, according to the pop-
ulation values. RESULTS: Mean global utility SF-6D scores were
0.70, and ranged from 0.73 (18–24 years) to 0.63 (55–64 years).
The mean utility scores were 0.17 lower in the lower educational
level than in the higher educational level (p < 0.000). Women,
people living in rural areas and the elderly reported lower levels
of utility scores. Nonparametric tests showed that health utility
values were signiﬁcantly related to employment (p < 0.000): the
unskilled manual workers (0.68) reported lower utility values
than the non-manual workers (0.74). For different diseases mean
utility scores ranged from 0.66 (hepatitis) to 0.56 (stroke). This
study was able to achieve normative data by age and gender for
the SF-6D. Using QALYs as outcome measures, the difference
between unskilled manual workers and non-manual workers
would be equivalent to a difference of 4902€ in annual income.
In this line of thinking, the difference between lower educational
level and higher educational level would be equivalent to a 
difference of 13,889€ in annual income. CONCLUSION: We
conclude that the SF-6D is an efﬁcient tool for measuring the
HRQOL in the community, so that different population groups
can be compared. The preference-based utility measure used
seems to adequately discriminate across different sociodemo-
graphic differences, showing that the HRQOL varies greatly
between sociodemographic groups.
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RECENT TREND IN MANAGEMENT OF
HYPERCHOLESTEROLEMIA AND GOAL ATTAINMENT
Goettsch WG
PHARMO Institute for Drug Outcomes Research, Utrecht,The
Netherlands
OBJECTIVES: To evaluate current lipid management practice in
The Netherlands and estimate the impact of new guidelines of
the European Society of Cardiology (ESC) on cholesterol goal
attainment. METHODS: Data were obtained from a sample of
the PHARMO system that includes complete medication, hospi-
tal admission and clinical lab assessment data of 80,000 Dutch
residents. Patients starting lipid lowering drug (LLD) therapy
between 2002–2004 who had a baseline TC measurement in the
six months prior to initiation of therapy and had at least one TC
measurement after the start of therapy were included. Goal
attainment was compared using the ESC 1998 and ESC 2003
guidelines. For both guidelines goal attainment was in general
deﬁned as TC <5mmol/l during LLD treatment. However, in 
the ESC 2003 guidelines goal attainment was deﬁned as TC 
<4.5mmol/l during LLD treatment for patients with cardiovas-
cular disease or diabetes. Doses of statins were expressed in
equipotencies based on TC lowering capabilities. RESULTS: The
study sample comprised of 623 patients (43% females). Most
patients (83%) were initiated on statin monotherapy of at least
an equipotent dose of four (simvastatin 20mg or equipotent
statin). Overall TC goal attainment rate based on 1998 guide-
lines was 59% and based on new ESC guidelines was 49%. Goal
attainment in patients with cardiovascular disease or diabetes
changed from 69% to 49% based on old and new guidelines
respectively. Our results also indicated that persistent statin use
during follow-up increased goal attainment (54% versus 44% in
not persistent patients using new ESC guidelines). CONCLU-
SIONS: Though lipid management in recent years has become
more aggressive, achievement of cholesterol goals based on the
new ESC guidelines is relatively low. Therefore there is a need
for highly effective lipid lowering therapies that are also well tol-
erated in order to achieve sufﬁcient persistence.
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IMPACT OF NEW EUROPEAN (ESC 2003) GUIDELINES 
ON TREATMENT OF HYPERCHOLESTEROLEMIA IN 
DAILY PRACTICE
Goettsch WG
PHARMO Institute for Drug Outcomes Research, Utrecht,The
Netherlands
OBJECTIVES: To compare lipid management and reductions in
total cholesterol (TC) levels among patients initiated on lipid
lowering drugs (LLD) in recent years (2002–2004) to those ini-
tiated in earlier years (1991–2001). METHODS: Data were
obtained from a sample of the PHARMO system that includes
complete medication, hospital admission and clinical lab assess-
ment data of 80,000 Dutch residents. Patients starting LLD
therapy and having a baseline TC measurement within six
months prior to therapy initiation as well as at least one mea-
surement after the start of therapy were included in two study
cohorts. One cohort included patients who initiated therapy in
2002–2004 and another that initiated therapy in 1991–2001.
Goal attainment was deﬁned as TC <5mmol/l during LLD treat-
ment according to Dutch guidelines. Statin dosage was expressed
in equipotencies based on TC lowering capabilities. RESULTS:
Patients with cholesterol levels <6mmol/l were more likely to be
treated in the period 2002–2004 than in the period 1991–2001
(27% versus 15% of all patients, respectively). Furthermore,
equipotent dose at the start of statin monotherapy gradually
